絞り込み

16555

広告

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.

著者 Glatt S , Baeten D , Baker T , Griffiths M , Ionescu L , Lawson ADG , Maroof A , Oliver R , Popa S , Strimenopoulou F , Vajjah P , Watling MIL , Yeremenko N , Miossec P , Shaw S
Ann Rheum Dis.2017 Dec 23 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (31view , 0users)

Full Text Sources

Medical

Miscellaneous

Interleukin (IL)-17A has emerged as pivotal in driving tissue pathology in immune-mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and overlapping biological function, remains less clear. We hypothesised that IL-17F, together with IL-17A, contributes to chronic tissue inflammation, and that dual neutralisation may lead to more profound suppression of inflammation than inhibition of IL-17A alone.
PMID: 29275332 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード